Cargando…

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

Multiple myeloma is a plasma cell malignancy that escapes from apoptosis by heterogeneously over-expressing anti-apoptotic BCL2 proteins. Myeloma cells with a t(11;14) translocation present a particular vulnerability to BCL2 inhibition while a majority of myeloma cells relies on MCL1 for survival. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seiller, Carolane, Maiga, Sophie, Touzeau, Cyrille, Bellanger, Céline, Kervoëlen, Charlotte, Descamps, Géraldine, Maillet, Laurent, Moreau, Philippe, Pellat-Deceunynck, Catherine, Gomez-Bougie, Patricia, Amiot, Martine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200824/ https://www.ncbi.nlm.nih.gov/pubmed/32371863 http://dx.doi.org/10.1038/s41419-020-2505-1

Ejemplares similares

Targeting Oxidative Stress With Auranofin or Prima-1(Met) to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells
por: Tessoulin, Benoit, et al.
Publicado: (2019)

Endogenous Bak inhibitors Mcl-1 and Bcl-x(L): differential impact on TRAIL resistance in Bax-deficient carcinoma
por: Gillissen, Bernhard, et al.
Publicado: (2010)

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
por: Chiron, David, et al.
Publicado: (2015)

MCL-1ES Induces MCL-1L-Dependent BAX- and BAK-Independent Mitochondrial Apoptosis
por: Kim, Jae-Hong, et al.
Publicado: (2013)

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
por: Tessoulin, Benoît, et al.
Publicado: (2019)

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
por: Champion, Ophélie, et al.
Publicado: (2023)

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups
por: Gomez-Bougie, Patricia, et al.
Publicado: (2014)

Mcl-1 promotes survival of thymocytes by inhibition of Bak in a pathway separate from Bcl-2
por: Dunkle, Alexis, et al.
Publicado: (2010)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors
por: Senichkin, Viacheslav V., et al.
Publicado: (2021)

Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1’s inhibitory effect on Bak
por: Wang, Chunxin, et al.
Publicado: (2011)

Delayed apoptosis by neutrophils from COPD patients is associated with altered bak, bcl-xl, and mcl-1 mRNA expression
por: Zhang, Jisong, et al.
Publicado: (2012)

Biphasic onset of splenic apoptosis following hemorrhagic shock: critical implications for Bax, Bcl-2, and Mcl-1 proteins
por: Hostmann, Arwed, et al.
Publicado: (2008)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma
por: Kervoëlen, Charlotte, et al.
Publicado: (2015)

Vaccinia Virus F1L Interacts with Bak Using Highly Divergent Bcl-2 Homology Domains and Replaces the Function of Mcl-1
por: Campbell, Stephanie, et al.
Publicado: (2010)

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
por: Descamps, G, et al.
Publicado: (2012)

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
por: Maïga, S, et al.
Publicado: (2013)

Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
por: Brosseau, C, et al.
Publicado: (2014)

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways
por: Tessoulin, Benoît, et al.
Publicado: (2018)

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
por: Chiron, D, et al.
Publicado: (2013)

Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
por: Robinson, Edward J., et al.
Publicado: (2018)

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane
por: O'Neill, Katelyn L., et al.
Publicado: (2016)

The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved?
por: Luo, Xu, et al.
Publicado: (2020)

Study of the Bcl-2 Interactome by BiFC Reveals Differences in the Activation Mechanism of Bax and Bak
por: Gonzalo, Óscar, et al.
Publicado: (2023)

Retinal ischemia-induced apoptosis is associated with alteration in Bax and Bcl-x(L) expression rather than modifications in Bak and Bcl-2
por: Produit-Zengaffinen, Nathalie, et al.
Publicado: (2009)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-X(L) and Mcl-1 but in the absence of active BH3-only proteins
por: Senft, D, et al.
Publicado: (2015)

Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
por: Mena, Salvador, et al.
Publicado: (2012)

Selective Affimers Recognise the BCL‐2 Family Proteins BCL‐x(L) and MCL‐1 through Noncanonical Structural Motifs
por: Miles, Jennifer A., et al.
Publicado: (2020)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2
Publicado: (1995)

Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-x(L) Binding to Bim
por: Cheng, Chunwei, et al.
Publicado: (2014)

Combined reduction in the expression of MCL-1 and BCL-2 reduces organismal size in mice
por: Ke, Francine, et al.
Publicado: (2020)

Correction to: Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
por: Robinson, Edward J., et al.
Publicado: (2022)

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression
por: Yasuda, Yuto, et al.
Publicado: (2020)

Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma
por: Gratas, Catherine, et al.
Publicado: (2014)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
por: Abdul Rahman, Siti Fairus, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3ld0ep9gtufqnjnljg3elqvva5